Table 4.

Drug-associated costs (€) per patient

Drug	Screening	Year 1	Year 2	Year 3	Year 4	Sum	Difference to cladribine
Cladribine
Adverse event	0	24	24	24	24	95	NA
Drug acquisition	0	34,376	34,376	0	0	68,753	NA
Monitoring	501	461	350	320	320	1952	NA
Productivity loss	71	93	116	48	48	376	NA
Travelling	46	53	61	39	39	238	NA
Sum	619	35,007	34,927	430	430	71,413	NA
Fingolimod
Adverse event	0	15	15	15	15	58	− 37
Drug acquisition	0	21,396	20,969	20,969	20,969	84,303	15,550
Monitoring	385	1175	334	334	334	2562	610
Productivity loss	71	297	70	70	70	579	203
Travelling	46	151	46	46	46	335	98
Sum	502	23,034	21,434	21,434	21,434	87,837	16,424
Natalizumab
Adverse event	0	0	0	0	0	0	− 95
Drug acquisition	0	27,000	27,000	27,000	27,000	108,000	39,247
Drug administration	0	3728	3728	3728	3728	14,913	14,913
Monitoring	396	320	320	471	471	1978	25
Productivity loss	68	590	590	635	635	2517	2141
Travelling	45	491	491	506	506	2040	1803
Sum	509	32,129	32,129	32,340	32,340	129,448	58,035
Treatment mix
Adverse event	0	12	12	12	12	47	− 48
Drug acquisition	0	22,517	22,175	22,175	22,175	89,042	20,290
Drug administration	0	746	746	746	746	2983	2983
Monitoring	387	1004	331	362	362	2445	493
Productivity loss	71	355	174	183	183	967	591
Travelling	46	219	135	138	138	676	439
Sum	504	24,853	23,573	23,615	23,615	96,159	24,746